TO CONNECT TO ISHEID 2021 ONLINE PLATFORM CLICK HERE

ISHEID You can also open you browser and go on: https://conferencify.io/ISHEID/Lobby International Symposium on HIV and Emerging Infectious Diseases CLICK HERE To connect to ISHEID 2021 online Virtual edition - May 17-20, 2021

La soumission des abstracts est prolongée jusqu'au 26 février !

2018/02/26 23:59:59

ISHEID 2021

Dear Friends, dear Colleagues,

We are pleased to welcome you to ISHEID, the International Symposium on HIV and Emerging Infectious Diseases.

The understanding of HIV and hepatitis infections continues to grow rapidly, especially regarding our ability to develop novel prevention and therapeutic strategies that will lead to the reduction of new infections. The burden of non-communicable diseases in HIV infected subjects implicates a multidisciplinary approach of the infection and the need of close interactions with specialists from other disciplines.

ISHEID 2021 dedicates a privileged place to state-of-the-art presentations, as well as to debates among experienced and younger investigators regarding new data and their implications.
This event has invited lectures by European and international leaders, many oral abstract and poster presentations, and educational workshops, as well as overviews of comorbidities by specialists of each field.

It is unique in its approach, as it engages basic scientists and clinicians from the HIV, hepatitis and emerging infectious diseases fields, as well as leading scientists involved in comorbidities.
We wish you a pleasant congress.

Alain LAFEUILLADE
on behalf of the steering committee

L’ISHEID 2021

Chers Collègues, chers Amis,

Nos connaissances sur l’infection par le VIH et les hépatites ne cessent de s’améliorer, notamment en ce qui concerne la mise en place de nouvelles stratégies thérapeutiques et de prévention dont l’objectif est de réduire le nombre de nouvelles infections. La charge des comorbidités chez les patients atteints par le VIH nécessite non seulement une approche multidisciplinaire de l’infection, mais également des échanges pointus avec des spécialistes d’autres disciplines.

L’ISHEID 2020 accordera une place privilégiée aux présentations à la pointe de l’actualité, de même qu’aux échanges entre médecins expérimentés et jeunes chercheurs au sujet des nouveautés et de leurs répercussions.

Le Congrès proposera des conférences animées par des leaders européens et internationaux, de nombreuses communications orales et posters, ainsi que des ateliers de formation et des présentations faites par des spécialistes de la gestion des comorbidités.

Le Congrès de l’ISHEID se démarquera par son approche originale en accueillant des scientifiques et des cliniciens qui exercent dans les domaines du VIH, des hépatites et des maladies infectieuses émergentes, ainsi que d’éminents spécialistes des comorbidités.

Nous vous attendons nombreux en mai 2020.

Alain LAFEUILLADE
au nom du comité de pilotage

MONDAY, MAY 17, 2021

LESSONS FROM COVID-19: PITFALLS AND PROMISE (In partnership with the EACS Young Investigators) / LES LEÇONS DE LA COVID-19 : PIÈGES ET PROMESSES (en partenariat avec les jeunes chercheurs de l’EACS)

17:30

Chairs: Christina PSOMAS, European Hospital, Marseille, France Annemarie WENSING, University Medical Center Utrecht, Netherlands Moderator: Tristan BARBER, Royal Free London NHS Foundation Trust, London, England


HIV and COVID-19 / VIH et COVID-19
Christoph SPINNER, Munich, Germany

Research pitfalls; what COVID has taught us / Les pièges de la recherche : ce que le COVID-19 nous apprend
Laura WATERS, London, England

HIV CURE / LA GUÉRISON DU VIH

18:45

Chairs: Sabine KINLOCH, Institute of Immunity & Transplantation, London, England Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada


Therapeutic simplification strategies in HIV infection and new ART strategies (2DR, triple regimen) / La simplification des stratégies thérapeutiques et les stratégies antirétrovirales chez les patients atteints par le VIH (2DR, triple regimen)
Jeff MURRY, Foster City, USA

Dual therapy against tritherapy: inflammation Vs toxicity / Les bithérapies contre les trithérapies : inflammation Vs toxicité
Christina PSOMAS, Marseille, France
Casper ROKX, Rotterdam, the Netherlands

BEST ORAL COMMUNICATIONS / MEILLEURES COMMUNICATIONS ORALES

20:00

Chairs: Guido POLI, Vita-Salute San Raffaele University, Milano, Italy Santiago MORENO, Hospital Ramón y Cajal, Madrid, Spain


O1. Impact of early antiretroviral therapy on tissue resident myeloid cells in the liver and lung of SIV-infected rhesus macaques
Authors: J. CLAIN, H. RABEZANAHARY, G. RACINE, G. BENMADID-LAKTOUT, O. ZGHIDI-ABOUZID, J. ESTAQUIER
Quebec University Hospital, Laval University, Research Center, Quebec - Canada

O2. Sexual satisfaction in women living with HIV. Are they the forgotten ones?
Authors: L. GONZÁLEZ RODRÍGUEZ1, J. BALIÑAS2, R. SCHULTZE3, L. LABAJO3, M.D.G. MUÑOZ3, Á. MENA2
1Obstetrics And Gynecology Service, Álvaro Cunqueiro University Hospital, Vigo - Spain
2Infectious Pathology Unit, A Coruña University Complex, A Coruña - Spain
3Infectious Pathology Unit, Álvaro Cunqueiro University Hospital, Vigo - Spain

O3. Influence of Hepatitis E virus genetic variability on the viral circulation between humans and environment
Authors: E. SCHVOERER1, C. HARTARD1, H. FENAUX1, A. DE ROUGEMONT2, E. LAUGEL1, S. BERGER1,J.P. BRONOWICKI3, I. BERTRAND4
1Nancy University Hospital, Laboratory of Virology, Vandœuvre-Lès-Nancy - France
2Dijon University Hospital, Laboratory of Virology, Dijon - France
3Nancy University Hospital, Hepato-Gastroenterology, Vandoeuvre Les Nancy - France
4 Lcpme (laboratoire De Chimie Physique Et Microbiologie Pour Les Matériaux Et L'environnement), Umr 7564Cnrs-Ul, Campus Santé Brabois, Vandoeuvre Les Nancy - France

O4. Effect of Metformin in non-diabetic people living with HIV: weight loss, decrease in inflammation and modification of the gut microbiota
Authors: S. ISNARD1, J. LIN1, T. VARIN2, A. MARETTE2, D. PLANAS3, C. VAN DER LEY4, P. ANCUTA3, J.P. ROUTY1
1Mcgill University Health Centre, Montreal - Canada
2Laval University, Québec - Canada
3 Montreal University, Montreal - Canada
4University Of Groningen, Groningen - Netherlands

O5. Extensive proteomic and transcriptomic changes quench the TCR/CD3 activation signal in latently HIV-1 infected T cells
Authors: E. CARLIN, B. GREER, A. DUVERGER, F. WAGNER, D. MOYLAN, A. DALECKI, S. SABBAJ, O. KUTSCH UAB, Birmingham - United States

DP1. Tracing the patterns of HIV-1 transmission among individuals with different diagnosis status in Greece
Authors: E-G. KOSTAKI1, S. LIMNAIOS1, S. PATRINOS2, D. CHATZIDIMITRIOU3, G. MAGIORKINIS1, L. SKOURA3, V. SYPSA1, A. HATZAKIS1, D. PARASKEVIS1
1Department Of Hygiene, Epidemiology And Medical Statistics, Medical School, National And Kapodistrian University Of Athens, Athens - Greece
2Hellenic Center For Diseases Control And Prevention, Marousi - Greece
3 National Aids Reference Center Of Northern Greece, Department Of Microbiology, Aristotle University Medical School, Thessaloniki - Greece

DP2. Identification of fast-growing HIV-1 transmission clusters in Spain and its potential application in Public Health
Authors: H. GIL, E. DELGADO, S. BENITO, M. SÁNCHEZ, J. CAÑADA, E. GARCÍA-BODAS, M.M. THOMSON,
Spanish group for the study of new HIV diagnoses
National Microbiology Centre. Carlos III Health Institute, Majadahonda - Spain

DP3. No impact of SARS-CoV-2 on the Activation Status of ART+HIV+ Patients
Authors: M. NIKOLOVA1, R. EMILOVA1, Y. TODOROVA1, N. YANCHEVA2, I. ALEXIEV3, R. GROZDEVA2, D. STRASHIMIROV2,N. KUYCHUKOVA2
1Nrl Of Immunology, National Centre Of Infectious And Parasitic Diseases, Sofia - Bulgaria
2Specialized Hospital for Active Treatment of Infectious and Parasitic Diseases, Sofia - Bulgaria3Nrl Of HIV, National Center of Infectious and Parasitic Diseases, Sofia - Bulgaria

DP4. Factors associated with willingness to participate in end-of-life cure research: perspectives from People Living with HIV
Authors: D. LESSARD1, M. BILODEAU2, P. KEELER3, J.P. ROUTY4, E.A. COHEN5, K. DUBÉ6, B. LEBOUCHÉ1,C. COSTINIUK4
1Canadian Institutes Of Health Research Strategy For Patient-Oriented Research Mentorship Chair In Innovative Clinical Trials, Montreal - Canada
2Ontario Aids Network, Toronto - Canada
3Aids Community Care Montreal, Montreal - Canada
4Research Institute of the Mcgill University Health Centre, Montreal - Canada
5Montreal Institute of Clinical Research, Department of Microbiology, Infectiology and Immunology, Montreal University,Montreal - Canada
6Public Health Leadership Program, University Of North Carolina At Chapel Hill And Chapel Hill And Gilings School Of Global Public Health, Chapel Hill - USA

DP5. Fibrosis regression in HIV-HCV coinfected patients treated by DAAs
Authors: G. LAURICHESSE1, P. JAFFEUX2, A. MIRAND3, N. MROZEK1, M. VIDAL1, V. CORBIN1, H. LAURICHESSE1,C. JACOMET1
1Clermont-Ferrand University Hospital, Infectious Diseases, Clermont-Ferrand - France
2Clermont-Ferrand University Hospital, Statistics, Clermont-Ferrand - France
3Clermont-Ferrand University Hospital, Virology, Clermont-Ferrand - France

DP6. Differential Serotyping of HEV genotype 1 and 3
Authors: M. SHATA1, E. ABDEL-HAMEED1, S. ROUSTER1, H. HETTA2, K. SHERMAN3
1University of Cincinnati, Cincinnati - USA
2Department of Medical Microbiology and Immunology, Faculty of Medicine,Assiut University, Assiut - Egypt
3University of Cincinnati, Internal Medicine, Digestive Dis., Cincinnati - USA



TUESDAY, MAY 18, 2021

VACCINES / LES VACCINS

17:00

Moderator: Diana FINZI, National Institute of Health, Bethesda, USA Jean-Pierre ROUTY, McGill University Health Centre, Montreal, Canada


Vaccines update for HIV and immunosuppressed patients / Calendrier vaccinal pour les PVVIH et les patients immunodéprimés
Anna-Maria GERETTI, London, England

Post-infection Vs post-vaccinal SARS-CoV-2 immunity: challenges and reality / Post-infection Vs l’immunité acquise grâce au vaccin : défi et réalité
Olivier SCHWARTZ, Paris, France

QUALITY OF LIFE MATTERS! TAILOR CARE TO OPTIMIZE IT IN PLWH
Symposium sponsored by MSD/ symposium parrainé par MSD

18:15

Moderator: Jonathan Schapiro, Sheba, ISR

Welcome and introduction
Jonathan Schapiro, Sheba, ISR

Future of NNRTIs: State of the ART of NNRTI resistance
Jonathan Schapiro, Sheba, ISR

Tailoring care for the body
Paddy Mallon, Dublin, IRL

Tailoring care for women with HIV
Karine Lacombe, Paris, FRA

Q&A

COMORBITIES AND MICROBIOTE / COMORBIDITÉS ET MICROBIOTE

19:30

Chairs: Jose Ignacio BERNARDINO, La Paz University Hospital, Madrid, Spain Christina PSOMAS, European Hospital, Marseille, France


The microbiome / Le microbiome
Sergio SERRANO VILLAR, Madrid, Spain

NASH and obesity and weight gain in hepatitis and HIV / La NASH chez les personnes atteintes par une hépatite ou par le VIH
Paddy MALLON, Dublin, Ireland

Role of hepatotropic viruses in the pathogenesis of cancer in PLWH / Le rôle des virus hépatotropes dans la pathogénèse du cancer chez les PVVIH
Alvaro MENA, Coruna, Spain

O6. Myocardial abnormailties in HIV: Insights from Cardiac Magnetic Resonacne Imaging (MRI)
Authors: G. MANMATHAN1, L. CHACKO2, R. MURKI2, T. KOTECHA2, C. LITTLE2, T. BARBER1,S. KINLOCH1, M. JOHNSON1, R. RAKHIT2
1Royal Free Hospital, London - United Kingdom
2University College London, London - United Kingdom

O7. Cardiomyopathy, pulmonary hypertension and myocarditis not as prevalent in well controlled
HIV: H-ART to Heart study
Authors: G. MANMATHAN, N. NGWU, J. JOHNSON, C. LITTLE, T. KOTECHA, M. JOHNSON, R. RAKHIT
Royal Free Hospital, London - United Kingdom

DP7. Nlrp3 inflammasome activation in peripheral blood leukocytes from HIV-infected patients and its contribution to chronic inflammation
Authors: V. NUNES CORDEIRO LEAL, E.C. DOS REIS, A. PONTILLO
University Of Sao Paulo, Sao Paulo - Brazil



WEDNESDAY, MAY 19, 2021

HOW TO END THE HIV PANDEMIC? / COMMENT ÉRADIQUER LA PANDÉMIE DE VIH ?

17:00

Chairs: Caroline SABIN, Royal Free Campus, London - England Christina PSOMAS, European Hospital, Marseille, France


London experience / L’expérience londonienne
Alison BROWN, London, England

Fast track cities, where are we? / Les fast-track cities : où en sommes-nous ?
Bertrand AUDOIN, Paris, France

BEYOND VIRAL SUPPRESSION, WHAT ARE THE CHALLENGES IN THE MANAGEMENT OF HIV INFECTION IN 2021?
Symposium sponsored by GILEAD/ symposium parrainé par GILEAD

18:15

Moderator: Christina Psomas

Inflammation and Immune markers
Christina Psomas, Montpellier, FRA

Sleep disorders and depression
Anne Moroy, Lille, FRA

Prevention and management of drug drug interactions
Olivier Robineau, Tourcoing, FRA

SARS-COV-2

19:30

Chairs: Valérie POURCHER, Hôpital de la Pitié-Salpêtrière, Paris, France Hervé TISSOT DUPONT, Aix-Marseille University, Marseille, France


Neurological complications of COVID-19, in acute disease and long-term / Les complications neurologiques de la COVID-19, dans les maladies aiguës et au long cours
Arvid EDÉN, Gothenburg, Sweden

Genetic determinants of COVID-19 disease severity / Les déterminants génétiques qui ont un impact sur la gravité de la COVID-19
Manuel CORPAS, Cambridge, England

DP8. Viral rebound (VR) 14 years after discontinuation of antiretroviral therapy (ART)
Authors: S. KINLOCH-DE LOES1, L. VANDEKERCKHOVE2, F. BURNS3, M. JOHNSON1
1Royal Free Hospital, London - United Kingdom
2University of Ghent, Ghent - Belgium
3Ucl, London - United Kingdom

DP9. Frailty phenotype is associated with antiretroviral exposure among older persons living with HIV
Authors: G. FELKER1, P. ENEL1, N. PETIT1, I. RAVAUX1, A. DARQUE1, F. RETORNAZ2
sup1Public University Hospital of Marseille, Marseille - France
2Department Of Public Health, Self-Perceived Health Assessment Research Unit Ea3279,Aix-Marseille University, Marseille - France

THURSDAY, MAY 20, 2021

CLIMATE AND SOCIO-POLITICAL CHANGES, HIV AND EPIDEMICS / CHANGEMENTS CLIMATIQUES ET SOCIO-POLITIQUES, VIH ET ÉPIDÉMIES

17:00

Chairs: Stephano VELLA, Superior Health Institute, Rome, Italy Ferdinand WIT, Academic Medical Center Amsterdam, Netherlands


HIV and global health in the era of coronavirus
Stefano VELLA, Rome, Italy

HTLV-1 has become a new STI
Carmen DE MENDOZA, Madrid, Spain

LONG-TERM VIROLOGICAL AND CLINICAL IMPACT OF DUAL THERAPY / IMPACT VIROLOGIQUE ET CLINIQUE LONG TERME DE LA BITHÉRAPIE
Symposium sponsored by VIIV HEALTHCARE/ symposium parrainé par VIIV HEALTHCARE

18:15

Moderator: Christine KATLAMA, Paris, FRA

Dual therapies: what are the impacts on HIV reservoirs? / Bithérapies : quels sont les impacts sur les réservoirs du VIH ?
Véronique Avettand-Fenoel. MCU-PH - UNIVERSITE PARIS , CHU Necker-Enfants Malades, Paris, FRA

What is the impact of long term dual therapy on bone, renal,inflammation and metabolics? / Quel est l'impact de la bithérapie à long terme sur l'os, le rein,l'inflammation et le métabolisme ?
Laura Waters, FRCP MD. Mortimer Market Centre, CNWL, London, UK

SEXUALLY TRANSMITTED INFECTIONS / LES INFECTIONS SEXUELLEMENT TRANSMISSIBLES

19:30

Chairs: Patricia ENEL, Aix-Marseille University, Marseille, France Patrick PHILIBERT, European Hospital, Marseille, France


Impact of COVID on sexual behaviour/risks/testing/ L'impact de la COVID sur les comportements/risques/essais sexuels
Cath MERCER, London, England

New challenges in STIs: M. Genitalium, XDR N.gonorrhoeae / Les nouveaux défis parmi les IST : M. Genitalium, XDR N.gonorrhoeae
Vicente SORIANO, Madrid, Spain

O8. Sexual Transmission of HTLV-1 and expanded spectrum of clinical manifestations
Authors: V. SORIANO1, J.M. RAMOS2, H. PINARGOTE2, C. DE MENDOZA3, A. SPANISHH T L V NETWORK3
1Unir Health Sciences School & Medical Center, Madrid - Spain
2General University Hospital & Miguel Hernandez University, Alicante - Spain
3Puerta De Hierro University Hospital & San Pablo University-Ceu, Madrid - Spain

DP10. HIV-2 in Spain - steadily increasing and new challenges
Authors: V. SORIANO1, T. CABEZAS2, E. CABALLERO3, A.B. LOZANO2, C. DE MENDOZA4
1Unir Health Sciences School & Medical Center, Madrid - Spain
2Hospital De Poniente, Almeria - Spain
3Hospital Vall D'hebron, Barcelona - Spain
4Puerta De Hierro Research Institute, Madrid - Spain


mai 2017
Ouverture des
inscriptions
juillet 2017
Ouverture de la
soumission des abstracts
24 janvier 2018
Fin du tarif préférentiel
d'inscription
26 février 2018
Fermeture de la soumission
des abstracts
Fin mars 2018
Notification de statut
des abstracts
null

Discover the highlights

null

Whatch the 2020 sessions

null

Plan your congress

null

Follow the last scientific news

From now on, you can…

INSTITUTIONAL SPONSORS